Table 1. Baseline characteristics and treatment details.
| Characteristics | Grade 0–3 lymphopenia | Grade 4 lymphopenia | p-value |
|---|---|---|---|
| Age ≥60 years <60 years |
135 (29.4%) 324 (70.6%) |
23 (31.5%) 50 (68.5%) |
0.783 |
| Primary site Oral cavity Oropharynx Larynx Hypopharynx |
2 (0.4%) 232 (50.5%) 136 (29.6%) 89 (19.4%) |
1 (1.4%) 35 (47.9%) 18 (24.7%) 19 (26%) |
0.286 |
| Oral tobacco Yes No |
203 (44.2%) 256 (55.8%) |
36 (49.3%) 37 (50.7%) |
0.448 |
| Tobacco smoking (bidi) Yes No |
239 (47.9%) 220 (52.1%) |
32 (43.8%) 41 (56.2%) |
0.209 |
| Tobacco smoking (cigarette) Yes No |
91 (19.8%) 368 (80.2%) |
10 (13.7%) 63 (86.3%) |
0.261 |
| HPV (p16) * Positive Negative Equivocal Not done |
22 (9.5%) 159 (68.5%) 0 51 (20.7%) |
1 (2.9%) 28 (80%) 1 (2.9%) 5 (14.3%) |
0.067 |
| Cisplatin cumulative dose—200 mg/m2 Yes No |
365 (79.5%) 94 (20.5%) |
52 (71.2%) 21 (28.8%) |
0.126 |
| Nimotuzumab received Yes No |
247 (53.81%) 212 (46.2%) |
34 (46.57) 39 (53.43%) |
0.191 |
| Total radiotherapy dose ≥70 Grey <70 Grey |
403 (87.79%) 56 (12.20%) |
57 (78.08%) 16 (21.91%) |
0.873 |
| Radiotherapy received (100% of planned dose) Yes No |
431 (93.9%) 28 (6.1%) |
68 (93.2%) 5 (6.2%) |
0.794 |
| Radiotherapy received (100% of planned dose) Yes No |
432 (94.1%) 27 (5.9%) |
69 (94.5%) 4 (5.5%) |
1.00 |
*
HPV status was detected by p16 immunohistochemistry staining and is reported according to the College of American Pathologists criteria for patients with oropharyngeal cancer. Samples for which testing was possible in patients with oropharyngeal cancer.